Heat-Labile Enterotoxin IIa, a Platform To Deliver Heterologous Proteins into Neurons

Chen Chen,a Amanda Przedpelski,a William H. Tepp,b Sabine Pellett,b Eric A. Johnson,b Joseph T. Barbieriab

Medical College of Wisconsin, Microbiology and Molecular Genetics, Milwaukee, Wisconsin, USAa; The University of Wisconsin—Madison, Bacteriology, Madison, Wisconsin, USAb

ABSTRACT Cholera toxin (CT) and the related heat-labile enterotoxins (LT) of Escherichia coli have been implicated as adjuvants in human therapies, but reactivity upon intranasal delivery dampened efforts to develop other clinical applications. However, each CT family member variant has unique biological properties that may warrant development as therapeutic platforms. In the current study, a nontoxic variant of the heat-labile enterotoxin IIa (LTIIa) was engineered to deliver heterologous, functional proteins into the cytosol of neurons. As proof of principle, the LTIIa variant delivered two cargos into neurons. LTIIa delivered β-lactamase efficiently into cells containing complex gangliosides, such as GD1b, as host receptors. LTIIa delivery of β-lactamase was sensitive to brefeldin A, an inhibitor that collapses the Golgi compartment into the endoplasmic reticulum, but not sensitive to treatment with botulinum neurotoxin D (BoNT/D), an inhibitor of synaptic vesicle cycling. LTIIa delivered a single-chain, anti-BoNT/A camelid antibody that inhibited SNAP25 cleavage during post-BoNT/A exposure of neurons. Delivery of functional, heterologous protein cargos into neurons demonstrates the potential of LTII variants as platforms to deliver therapies to inactivate toxins and microbial infections and to reverse the pathology of human neurodegenerative diseases.

IMPORTANCE This study engineered a protein platform to deliver functional, heterologous proteins into neurons. The protein platform developed was a variant of the heat-labile enterotoxin IIa (LTIIa) which lacked the catalytic domain, yielding a nontoxic protein. As proof of principle, LTIIa variants delivered two functional proteins into neurons, β-lactamase and a camelid antibody. These studies show the utility of LTIIa variants to deliver therapies into neurons, which could be extended to inactivate toxins and microbial infections and potentially to reverse the progression of neurological diseases, such as Alzheimer’s disease and Parkinson’s disease.

New options have advanced medical therapies, including gene therapy, bactofection (bacteria as vectors for gene transfer), alternative gene therapy (AGT) (persisting bacteria produce therapeutic products in vivo), and protein therapeutics (1, 2). Protein therapeutics is both an early approach and an emerging field in medical therapeutics. Since the approval of insulin as a therapy (3), approximately 200 protein products that include therapeutic, diagnostics, and vaccines have been marketed (4). There are two common approaches to deliver heterologous proteins into cells, virus-based and protein-based. Protein-based therapies lack a genetic, infectious component, an advantage over virus-based therapy (5, 6). Current heterologous protein delivery platforms include protective antigen (PA) of anthrax toxin (7). PA delivery is efficient, but nonselective, since the anthrax toxin receptors are common among cell types (8), which limits PA as a cell-type-specific protein delivery platform (9). Immunotoxins (ITs) are another platform used for heterologous protein delivery (10, 11), and they are targeted by identifying receptors that have elevated expression of a host receptor on a targeted cell relative to “nontargeted” cells (12).

AB5 toxins are synthesized by several bacterial pathogens and plants and comprise a monomeric enzymatic A subunit and a binding (B) subunit pentamer. The A subunit is a single polypeptide composed of two domains, A1 and A2, which are linked together via a disulfide bond. The A1 domain encodes a catalytic domain responsible for toxicity to the host cell. The A2 domain consists of an α-helix that penetrates into the central pore of the B subunit, thereby noncovalently anchoring the A subunit and B subunits to create the holotoxin (13). There are four main families of AB5 toxins, cholera toxin (CT), pertussis toxin, Shiga toxin, and subtilase cytotoxin, which have been previously reviewed (13). The CT family includes CT of Vibrio cholerae and the heat-labile enterotoxins (LTs) of Escherichia coli: LT, LTII, LTIIb, and LTIIic (13). CT and LT enter host cells by binding gangliosides on the cell surface, leading to endocytosis and subsequent delivery of the A subunit into the host cell cytosol. CT and LT have been used as adjuvants that stimulate immunity or, alternatively, suppression of autoimmunity (14–16). However, enthusiasm for CT-based therapies waned when an adverse clinical outcome (Bell’s palsy) was detected in some patients treated with intranasal LT (K63) (17). An underappreciated property of the CT family of toxins is that individual members have unique biological properties. For
example, the LTII family members (LTIIα, LTIIβ, and LTIIε) share limited primary amino acid homology or biological properties with CT and LTII (18), and Connell and coworkers showed the utility of an LTIIβ variant as an adjuvant for a ricin toxin subunit vaccine (19). AB5 toxins have not been described as neuron-targeting protein delivery platforms.

Gangliosides are glycosphingolipids that contain sialic acids and are components of cell membranes. In the nervous system of higher vertebrates, complex gangliosides such as GM1α, GD1α, GD1b, and GT1b comprise about 80 to 90% of the total gangliosides (20), whereas the simple gangliosides GM2 and GM3 are more commonly displayed on extraneuronal tissue and are largely absent on brain tissue. CT and LTII use gangliosides as host receptors. CT, LTII, and LTIIε bind GM1α. LTIIα binds GD1b, and LTIIβ binds GD1a and other less-complex gangliosides at a lower affinity (21). Since complex gangliosides, such as GM1α, GD1α, GD1b, and GT1b, enriched neurons, LTII family members are candidates for neuron-specific protein delivery platforms.

In the current study, LTIIα is shown to deliver two functional protein cargos into the host cells, β-lactamase (βlac), which was biologically functional within the host cell cytosol, and an ~14-kDa camelid single-domain antibody that neutralized botulinum neurotoxin type A (BoNT/A) in neurons preexposed to the toxin. This shows proof of principle for the development of LTII toxin variants as protein delivery platforms for neurons.

RESULTS

βlac is catalytically active in neuronal cells. A fluorescence resonance energy transfer (FRET)-based assay (22) was used to measure β-lactamase (βlac) in the cytosol of neuronal cells. Briefly, cells were incubated with CCFlac-AM, a heterocyclic small molecule, which passes across cell membranes and is converted by cytosolic host esterase to CCFlac (23), a membrane-impermeant reagent. Intracellular CCFlac has FRET properties; upon excitation at 409 nm, CCFlac transfers fluorescence resonance energy at 520 nm (green), but when cleaved by βlac, CCFlac loses FRET, which shifts emission to 447 nm (shown as cyan for visualization). Neuro-2a cells were transfected with pβlac-DsRed or pβlacnull-DsRed and assayed for the excitation/emission profile of CCFlac. Cells expressing βlac-DsRed, but not enzymatically inactive βlacnull-DsRed, showed cyan fluorescence, which supported a β-lac-dependent cleavage of CCFlac (see Fig. S1 in the supplemental material). This showed the CCFlac-βlac reporter system to be functional in Neuro-2a cells.

βlac-LTIIα assembles into an AB5 protein. SDS-PAGE analysis assessed βlac-LTIIα assembly into an AB protein complex. Affinity-purified LTIIα, βlac-LTIIα, and βlacnull-LTIIα comprised two bands corresponding to the size of the A subunit or the βlac-A2 within the LTIIα chimera and B subunit, with B-A assembly ratios of 5.2 and 5.4, respectively. Since the proteins were purified with an affinity epitope located on the B subunit, the detection of the A subunits within LTIIα and βlac-LTIIα supported assembly within βlac-LTIIα (Fig. 1).

LTIIα delivers functional cargo (βlac) into neurons. Delivery of enzymatically active βlac by βlac-LTIIα into primary rat cortical neurons was next examined. Incubation of βlac-LTIIα with rat primary cortical neurons showed CCFlac cleavage (cyan), while LTIIα did not cleave CCFlac (Fig. 2A). βlac-LTIIα titration yielded a proportional amount of CCFlac cleavage, with βlac activity detected in cells treated with 0.1 nM βlac-LTIIα (Fig. 2B). This supports the ability of LTIIα to deliver a functional, heterologous protein (βlac) into neurons.

To further investigate the trafficking of the βlac (cargo) and B subunit of βlac-LTIIα, a FLAG epitope was engineered on the C terminus of βlac to detect cargo localization, while a hemagglutinin (HA) epitope was engineered to detect the B subunit. FLAG and HA epitopes had a Pearson coefficient (PC) of 0.64 upon...
incubation of βlac–LTIla with neurons at 4°C, indicating a baseline of colocalization when bound to the cell surface (Fig. 3). Upon incubation at 37°C, the PC of FLAG/HA decreased to 0.43, showing segregation of the two epitopes. This supports neuronal cell entry and separation of cargo from the B subunit of LTIla within neurons. In this experiment, we extrapolated that LTIla delivered >10,000 molecules of βlac into neurons, which suggests that this LTIla variant is efficient in delivering a heterologous cargo into a neuron.

LTIla binds GD1b ganglioside with the highest affinity and also binds GD1a, GT1b, GQ1b, GM1a, and GD2, with lower affinities (21). Neuro-2a cells do not express complex gangliosides such as GD1b; however, upon incubation with exogenous gangliosides, Neuro-2a cell membranes can be loaded with gangliosides (24). Upon incubation of Neuro-2a cells with exogenous gangliosides, LTIla delivered βlac ~2-fold more efficiently into GD1b-treated cells than GM1a-treated cells (Fig. 4A and B), consistent with LTIla having a higher affinity for GD1b than GM1a (21). As a control, cells incubated with LTIla and βlacnull–LTIla did not show a translocation signal (Fig. 4A and C). Brefeldin A (BFA), a fungal metabolite that inhibits vesicular transport in the secretory pathway and vesicular exchange between endosomes and Golgi cisternae/endoplasmic reticulum (ER) in most eukaryotic cells (25), inhibited βlac translocation by LTIla in GD1b-loaded Neuro-2a cells (Fig. 4C), supporting a Golgi compartment-mediated pathway for trafficking as native LTIla (26). HeLa cells were also tested for βlac–LTIla ganglioside specificity and cargo translocation efficiency. Similarly to Neuro-2a cells, GD1b-mediated entry of βlac was more efficient than GM1a-mediated entry of βlac. Neither GM2 nor GD2 mediated efficient entry of βlac (Fig. 5). Controls showed that in the absence of exogenous gangliosides, βlac delivery by βlac–LTIla was not detected in either Neuro-2a or HeLa cells, as shown by the dashed line in Fig. 5. βlac–LTIla delivered βlac more efficiently in neurons than in either Neuro-2a cells or HeLa cells. This suggests that neurons are a preferred target of βlac–LTIla (Fig. 5).

LTIla delivers functional cargo (βlac) into BoNT/D-intoxicated neurons. Botulinum neurotoxins cleave neuronal SNARE proteins to prevent synaptic vesicle fusion to the cell membrane. To determine if LTIla can deliver cargo into neurons that do not cycle synaptic vesicles, the ability of βlac–LTIla to deliver βlac into BoNT/D-intoxicated neurons was measured. Rat primary neurons were incubated overnight with BoNT/D to cleave endogenous VAMP2, which was confirmed by immunofluorescence (IF) staining (Fig. 6A and B). CCF2 cleavage by βlac–LTIla was similar in BoNT/D-treated neurons and control neurons (Fig. 6C). Translocation of βlac by βlac–LTIla was sensitive to BFA in BoNT/D-intoxicated neurons (Fig. 6C), supporting a Golgi compartment-mediated pathway for βlac trafficking. LTIla

![Figure 3](image-url) Delivery and separation of βlac from the B subunit during βlac–LTIla entry into neurons. (A) Rat primary cortical neurons were incubated with 40 nM βlac–LTIla at 4°C or 37°C for 60 min. Cells were washed, followed by IF staining, using anti-HA antibody (green) and anti-FLAG antibody (red). (B) Representative colocalization between HA and FLAG staining was shown by a cytofluorogram with Pearson’s coefficient (PC) determined. Bar, 20 μm.

![Figure 4](image-url) LTIla delivers cargo (βlac) more efficiently into GD1b-enriched Neuro-2a cells than GM1a-enriched Neuro-2a cells. (A) Neuro-2a cells were loaded with 10 μg/ml of ganglioside GD1b or GM1a in DMEM with 0.5% FBS at 37°C for 3 h. Cells were washed and incubated with 40 nM βlac–LTIla or LTIla at 37°C for 60 min. Cells were loaded with CCF2-AM at RT for 30 min, followed by IF staining using anti-HA antibody (red). Uncleaved CCF2 is shown in green, and cleaved CCF2 (CCF2c) is shown in cyan. (B) Cleaveage of substrate CCF2 was quantified using the CCF2c/CCF2/HA ratio of fluorescent intensities. (C) Neuro-2a cells were loaded with GD1b and then incubated with 40 nM βlac–LTIla, βlacnull–LTIla, or LTIla at 37°C for 60 min alone or with 0.1 μg/ml of brefeldin A (BFA). Cells were washed and were loaded with CCF2-AM at RT for 30 min. Cleavage of CCF2 was quantified using the CCF2c/CCF2/HA ratio of fluorescent intensities. Data were analyzed by two-tailed Student’s t test. *, P < 0.05; **, P < 0.005; ***, P < 0.001. Bar, 20 μm.
was next tested for the ability to deliver a BoNT therapeutic into neurons.

VHH-B8-LTIIa inhibits BoNT/A cleavage of SNAP25 in primary cortical neurons. An LTIIa variant was engineered where the A1 subunit was exchanged with a single-chain variable-region camelid antibody known to inhibit BoNT/A-LC (B8) (termed VHH-B8-LTIIa; GenBank accession number FJ643070) (27) (Fig. 7A). Primary cortical neurons were incubated with BoNT/A or BoNT/D for 2 h at 37°C, washed, and then incubated with various amounts of VHH-LTIIa for 3 h and assayed for cleaved SNAP25 (BoNT/A-treated cells) or degradation of full-length VAMP2 (BoNT/D-treated cells). Cleaved SNAP25 was detected in cells treated with BoNT/A alone, while BoNT/A-intoxicated cells treated with VHH-LTIIa showed a dose-dependent reduction of cleaved SNAP25 (Fig. 7B and D). Controls showed that VHH-LTIIa inhibition was BoNT serotype dependent, since VHH-LTIIa did not inhibit the cleavage of VAMP2 by BoNT/D (Fig. 7C and D). Similar results were observed when VHH-LTIIa was incubated with postintoxicated neurons overnight (Fig. 7E). Western blotting (WB), using an antibody that recognizes full-length and cleaved forms of SNAP25, showed that VHH-LTIIa partially inhibited BoNT/A cleavage of SNAP25, while VHH-LTIIa did not affect BoNT/D VAMP2 cleavage with overnight incubation in neurons (Fig. 8). This is the first example of the active delivery of a functional therapy into a BoNT-intoxicated neuron by AB5 toxin.

DISCUSSION

In this study, LTIIa was shown to deliver functional, heterologous proteins into neurons: βlac, as a reporter cargo, and a single-chain camelid antibody, as a BoNT therapy. βlac-LTIIa did not show “off-target” delivery of heterologous cargo into either Neuro-2a cells or HeLa cells, since βlac intracellular delivery into these cells required addition of exogenous gangliosides. βlac-LTIIa delivery was independent of synaptic vesicle cycling, consistent with LTIIa not entering synaptic vesicles. Overall, LTIIa appears to be a candidate platform to deliver heterologous proteins into neurons.

The intrinsic affinity of LTIIa for the complex ganglioside GD1b provides a delivery platform that is trophic for neurological tissue. βlac translocation was more efficient in neurons than in Neuro-2a and HeLa cells, suggesting that neurons are a preferred target of βlac-LTIIa (Fig. 5). Since GM1a mediated βlac translocation in Neuro-2a and HeLa cells, further studies need to modify LTIIa B subunit to enhance GD1b binding and decrease GM1a binding to make a more neuron-specific platform. The pentameric B subunits of LTIIb were reported to activate the Toll-like receptor 2 (TLR2)/TLR1 heterodimer when not associated with the A subunit (28). Four mutated pentameric B subunits, M69E, A70D, L73E, and S74D, were defective in TLR1/2 activation despite retaining full ganglioside-binding capacity (28). Those four residues are conserved between LTIIa and LTIIb (29). Corresponding modifications of LTIIa B subunits are planned to eliminate TLR interaction to reduce immune activity of the B subunit.

BoNTs, which are tier 1, category A select agents, deliver a light-chain protease to neurons, causing cleavage of one or more SNARE proteins involved in neurotransmission, which can extend flaccid paralysis for up to 6 months (30). The primary treatment of botulism is with an antitoxin (human botulinum immunoglobulin) and supportive care. While there are no approved BoNT therapies to clear intracellular BoNT in neurons, progress has been made toward BoNT therapies, including neutralizing antibodies and BoNT heavy-chain-based drug delivery systems (31–34). Delivery systems based on BoNT/A heavy chain (33, 34) and inactivated BoNT/B-coupled liposome (35) depend on synaptic vesicle recycling, as synaptic vesicle proteins SV2 and synap-
totagmin II are the protein receptors for BoNT/A and BoNT/B, respectively (36–38). However, BoNT-based delivery systems are inefficient for entry into BoNT-intoxicated neurons. In contrast, BoNT/D intoxication did not affect entry of \( \text{H9252} \) into neurons (Fig. 6). The current study shows that LTIIa could deliver a therapeutic camelid antibody (VHH) into BoNT/A-intoxicated neurons that partially inhibited BoNT/A action (Fig. 7 and 8), supporting the development of LTIIa to deliver therapeutics following BoNT intoxication. Thus, attention now focuses on engineering BoNT therapies that have a catalytic component for BoNT neutralization, such as the fusion of VHH-B8-D5 fusion proteins (39) to accelerate turnover of VHH-bound BoNT/A light chain, and the addition of an F-box domain region of TrCP (trans-)

**Figure Legend Continued**

or BoNT/D (C) was incubated with rat cortical neurons at \( 37^\circ \text{C} \) for 2 h, when toxin was removed and the indicated amount of VHH-B8-LTIIa (B8) was added to neurons for an additional 3 h. Cells were fixed and incubated with Alexa 647-wheat germ agglutinin (WGA; magenta) for 30 min as a cell marker. The IF assay stained for HA (red) and cleaved SNAP25 (SNAP25c, green) in BoNT/A-treated cells or intact VAMP2 (green) in BoNT/D-treated cells. (D) Cleavage was quantified by measuring the SNAP25c/WGA ratio of fluorescence intensities for BoNT/A-treated cells and the VAMP2/WGA ratio of fluorescence intensities for BoNT/D-treated cells. (E) BoNT/A or BoNT/D (1 nM) was incubated with rat cortical neurons at \( 37^\circ \text{C} \) for 2 h, when toxin was removed and the indicated amount of VHH-B8-LTIIa (B8) was added with neurons overnight. Cleavage was quantified as described for panel D. Data were analyzed as SEM by two-tailed Student’s \( t \) test. *, \( P < 0.05 \); **, \( P < 0.005 \).

Bar, 20 \( \mu \text{m} \). NS, not significant; o/n, overnight.
ducin repeats-containing protein) (D5), an E3 ubiquitin ligase receptor, has been used to accelerate turnover of the targeted BoNT/A protease (31, 39). An adenovirus-based delivery system for VHH-based therapies has been recently described (40).

Protein aggregation in the brain is a characteristic feature of neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease (41), where a therapeutic protein could be delivered to affected neurons. AB5 variants could also target latent viruses inside neurons, such as herpes zoster virus, which causes disease in 4 of every 1,000 healthy individuals each year, and a reported 10 cases per 1,000 individuals older than 75 years (42). In addition, LTIIa variants may also deliver therapeutics, either protein or non-protein based, to treat latent microbial infections in neurons.

MATERIALS AND METHODS

Antibodies. Antibodies were purchased from the vendors indicated: rat anti-HA antibody (Roche), mouse anti-FLAG M2 antibody (Sigma), mouse anti-VAMP2 (clone 69.1; SYSY), mouse anti-BoNT/A-cleaved SNAP25 (SNAP25c; 4F3-2C; Research and Diagnostic Antibodies; recognizing only BoNT/A-cleaved SNAP25 but not full-length SNAP25), mouse anti-SNAP25 (SMI-81R; Covance; recognizing both full-length and BoNT-cleaved SNAP25), Alexa Fluor-labeled secondary antibodies (Invitrogen), and Alexa 647-wheat germ agglutinin (WGA) (Invitrogen).

Plasmid construction. E. coli codon-optimized sequences of LTIIa (GenBank accession number JQ031711) A subunit and B subunit were synthesized with dual isopropyl-β-D-thiogalactopyranoside (IPTG)-inducible T7 promoters (GenScript) and subcloned into the pET28a vector for expression. His6 and HA2 epitopes were added to the C terminus of the B subunit for purification and immunofluorescence detection, respectively. LTIIa A subunit and B subunit genes encode leader sequences for cotranslational secretion into the periplasm. TEM-1 β-lactamase (βlac; GenBank sequence accession number AGW45163.1; amino acids 24 to 286) replaced the A1 subunit of LTIIa (amino acids 1 to 172), producing βlac-LTIIa (Fig. 1), which included 3 × FLAG downstream of the βlac. Site-directed mutagenesis (S45A) produced βlacmut-LTIIa, which lacked βlac activity. DNA encoding βlac and βlacmut were also subcloned into DsRedmonon1 to construct plβlac-DsRed and plβlacmut-DsRed, respectively. DNA encoding a single-domain 14-kDa camelid antibody (VHH) specific for BoNT/A (ALc-B8; GenBank accession number FJ643070; amino acids 7 to 121) with a C-terminal 3 × FLAG tag replaced the sequence encoding the A1 subunit of LTIIa (amino acids 1 to 172), yielding VHH-B8-LTIIa. Constructs were confirmed by DNA sequencing.

Protein expression and purification. Plasmids encoding LTIIa, βlac-LTIIa, βlacmut-LTIIa, and VHH-B8-LTIIa were transformed into E. coli BL21 (DE3). Transformants were grown on overnight LB agar plates containing 50 μg of kanamycin/mL, which were the inoculums for liquid cultures (LB, 400 mL) containing the same antibiotic. Cells were cultured at 37°C to an optical density at 600 nm (OD600) of 0.6 when T7 promoter expression was induced with 1 mM IPTG. Cells were cultured overnight at 250 rpm at 16°C. Cells were pelleted and suspended in 20 mL Tris (pH 7.9) with 25% sucrose. Cells were treated with lysozyme (0.16 mg/mL in 0.1 M EDTA) for 30 min on ice, followed by addition of 70 mM MgCl2 (final concentration) and centrifugation at 5,000 × g for 20 min to separate the soluble periplasm from the cells. His6-tagged proteins were purified from the periplasm, using Ni2+-nitrilotriacetic acid (NTA) resin (Qiagen). Purified proteins were dialyzed into 20 mM Tris buffer (pH 7.9) with 20 mM NaCl and 40% glycerol. Aliquots were stored at −80°C.

Cells and reagents. Neuro-2a cells (ATCC; CCL-131) and HeLa cells (ATCC; CCL-2) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) with 10% fetal bovine serum (FBS; Invitrogen). Cells were transfected with plβlac-DsRed or plβlacmut-DsRed with Lipofectamine LTX (Invitrogen) as suggested by the manufacturer. Rat primary cortical neurons were cultured in glass-bottomed 24-well plates (MatTek) at ~20,000 neurons/well as previously described (43). Briefly, rat E18 cortical neurons or rat E18 hippocampal neurons (BrainBits LLC) were cultured in neurobasal medium (catalog no. 21103; Invitrogen) supplemented with 0.5 mM GlutaMAX-I (catalog no. 35050; Invitrogen), 2% B27 supplement (catalog no. 17504; Invitrogen), and Primocin (InvivoGen). Half of the medium was replenished every 5th day. Neurons were used at day 10 to 14 postplating. Botulinum neurotoxin type D (BoNT/D) was isolated from Clostridium botulinum strain 1873. The 150-kDa protein was purified using methods similar to those previously described for isolation of toxins from other BoNT serotypes (44, 45). Specific activity in mice was 1.1 × 104 50% lethal dose (LD50) units/mg.

(i) βlac-LTIIa and LTIIa entry and translocation in Neuro-2a cells and primary cortical neurons. Neuro-2a cells and HeLa cells were loaded with 10 μg/mL of the ganglioside GD1b, GM1a, GD2, or GM2 in DMEM with 0.5% fetal bovine serum (FBS) at 37°C for 3 h. Cells were washed and incubated with 40 nM βlac-LTIIa or LTIIa in serum-free DMEM at 37°C for 60 min. Primary neurons were incubated with 40 nM LTIIa or βlac-LTIIa in neurobasal medium (supplemented with B27 and GlutaMAX) at 37°C or 4°C for 60 min. Cells were washed with Hank’s balanced salt solution (HBSS) and loaded with CCF2-AM dye (Invitrogen; 6 × prepared as suggested by the manufacturer to obtain a final concentration of 1 × in HBSS). Samples were incubated at room temperature (RT) for 30 min and washed, and IF staining was performed as described below.

(ii) Effects of VHH-B8-LTIIa on BoNT-intoxicated neurons. Rat cortical neurons were incubated with 1 nM BoNT/A or BoNT/D at 37°C for 2 h, toxin was removed, and indicated amounts of VHH-B8-LTIIa (B8) were incubated with neurons at 37°C for another 3 h. Cells were fixed and incubated with Alexa 647-wheat germ agglutinin for 30 min at room temperature (RT). Immunofluorescence (IF) staining, as described below, detected BoNT/A-cleaved SNAP25 (SNAP25c) or intact VAMP2 in BoNT/D-treated cells. Cleavage of SNARE substrates was quantified using the SNAP25c/WGA ratio of fluorescence intensities for BoNT/A-intoxicated cells and the VAMP2/WGA ratio for BoNT/D-intoxicated cells. In other parameters of this experiment, neurons were incubated with 1 nM BoNT/A or BoNT/D with the indicated amounts of VHH-B8-LTIIa at 37°C overnight, and SNARE substrate cleavage was evaluated as described above. Neurons were also incubated with 0.5 nM BoNT/A and BoNT/D with 20 nM VHH-B8-LTIIa at 37°C overnight, and SNARE substrate cleavage was evaluated by Western blotting (WB) using anti-SNAP25 antibody (recognizing both full-length and cleaved forms of SNAP25) and anti-VAMP2 antibody (recognizing full-length VAMP2).

IF staining. Cells were fixed with 4% (wt/vol) paraformaldehyde in Dulbecco’s phosphate-buffered saline (DPBS) for 15 min at RT, washed twice with DPBS, permeabilized with 0.1% Triton X-100 in 4% formaldehyde in DPBS for 15 min at RT, incubated with 150 mM glycine in DPBS for 10 min at RT, washed with DPBS twice, and subjected to immunofluorescence (IF) staining. Treated cells were incubated in blocking solution (10% normal goat serum, 2.5% cold fish skin gelatin [Sigma], 0.1% Triton X-100, 0.05% Tween 20 in DPBS) for 1 h (RT), followed with primary antibodies in antibody incubation solution (5% normal goat serum, 1% cold fish skin gelatin, 0.1% Triton X-100, 0.05% Tween 20 in DPBS) overnight at 4°C. Cells were washed three times with DPBS plus 0.05% Tween 20 and incubated with goat or rat IgG Alexa-labeled secondary antibodies (Invitrogen) in antibody incubation solution for 1 h (RT). Then, cells were washed 3 times, fixed with 4% paraformaldehyde in DPBS for 15 min (RT), and washed (DPBS). Mounting reagent Citifluor AF-3 (Electron Microscopy Sciences) was added, and images were captured with a Nikon TE2000 microscope using a Photometrics CoolSnap HQ2 camera. Images were captured by epifluorescence with a Sedat Quad cube (Chroma Technology Corp.). Cleaved CCF2 (CCF2c, shown as cyan in this paper for better visualization) was observed in the 4′,6-diamidino-2-phenylindole (DAPI) channel (AT350/50x, ET455/50m). Uncleaved CCF2 (shown as green) and Alexa 488 secondary antibody-labeled staining were observed in the fluorescein isothiocyanate (FITC) channel (ET490/20x, ET525/36m). Alexa 647-WGA was observed in the Cy5.
REFERENCES

1. Pálffy R, Gardlík R, Hodosy J, Behulák M, Resko P, Radvánková J, Celen P. 2006. Bacteria in gene therapy: bacteriocfection versus alternative gene therapy. Gene Ther 13:101–105. http://dx.doi.org/10.1038/sj.gth.3303263.5

2. Gardlík R, Pálffy R, Hodosy J, Lukács J, Turna J, Celen P. 2005. Vectors and delivery systems in gene therapy. Med Sci Monit 11:RA10–RA121.

3. Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD. 1979. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci U S A 76:106–110. http://dx.doi.org/10.1073/pnas.76.1.106.

4. Gierasch P. 1987. Biopolymeric mechanical properties. Nat Biotechnol 5:897–924. http://dx.doi.org/10.1038/nbt0991-917.

5. Heilmann C, van Samson P, Schlegel K, Attmann T, von Specht BU, Beyerdsorf F, Lutter G. 2002. Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2. Eur J Cardiothorac Surg 22:957–964. http://dx.doi.org/10.1016/S1078-5371(02)00577-8.

6. Cui M, Wan Y, Anderson DG, Shen FH, Lee BM, Laurencon CT, Balian G, Li X. 2008. Mouse growth and differentiation factor-5 protein and DNA therapy potentiates intervertebral disc cell aggregation and chondrogenic gene expression. Spine J 8:287–295. http://dx.doi.org/10.1016/j.spinee.2007.05.012.

7. Akamatsu Y, Murphy JC, Nolan KF, Thomas P, Kreitman RJ, Leung SO, Junghans RP. 1998. A single-chain immunotoxin against carcinoma-embryonic antigen that suppresses growth of colorectal carcinoma cells. Clin Cancer Res 4:2825–2832.

8. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414:225–229. http://dx.doi.org/10.1038/35109199.

9. Varughese M, Chi A, Teixeira AV, Nicholls PJ, Keith JM, Leysath CE, Ofori K, Baldwin K, Feng X, Blum FC, Przedpelski A, Tepp WH, Johnson EA, Barbieri JT. 2014. Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells. Infect Immun 82:873–881. http://dx.doi.org/10.1128/IAI.01539-13.

10. Lancer WI, Hirst TR, Holmes RK. 1999. Membrane traffic and the cellular uptake of cholera toxin. Biochim Biophys Acta 1429:411–418. http://dx.doi.org/10.1016/S0969-2126(96)00073-1.

11. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, Tzipori S, Shoemaker JD. 2004. Cholera toxin—a foe and a friend. Indian J Med Res 119:133:181–1824.

12. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. 2006. Immunotoxin therapy of cancer. Nat Rev Cancer 6:559–565. http://dx.doi.org/10.1038/nrc1891.

13. Beddoe T, Paton AW, Le Nours J, Rossjohn J, Paton JC. 2010. Structure, biological functions and applications of the AB5 toxins. Trends Biochem Sci 35:411–418. http://dx.doi.org/10.1016/j.tibs.2010.02.003.

14. Sanchez J, Holmgren J. 2011. Cholera toxin—a foe and a friend. Indian J Med Res 133:153–163.

15. McKenzie SJ, Halsey JF. 1984. Cholera toxin B subunit as a carrier protein for conjugation of a mucosal immune response. J Exp Med 159:3318–3324.

16. Bharati K, Ganguly NK. 2011. Cholera toxin: a paradigm of a multifunctional protein. Indian J Med Res 133:179–187.

17. Lewis DJ, Hsu Z, Barnett S, Kromann I, Giezena R, Galiza E, Woodrow M, Thierry-Carstensen B, Andersen P, Novicki D, Del Giudice G, Rappuoli R. 2009. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4:e6999. http://dx.doi.org/10.1371/journal.pone.006999.

18. Hajishengallis G, Connell TD. 2013. Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties. Vet Immunol Immunopathol 152:68–77. http://dx.doi.org/10.1016/j.vetimm.2012.09.034.

19. Greene CJ, Chadwick CM, Mandell LM, Hu JC, O’Hara JM, Brey RN, Mantis NJ, Connell TD. 2013. LT-IB (T31), a non-toxic Type II heat-labile enterotoxin, augments the capacity of a ricin toxin subunit vaccine to evoke neutralizing antibodies and protective immunity. PLoS One 8:e69678. http://dx.doi.org/10.1371/journal.pone.0069678.

20. Schwarz A, Futerman AH. 1996. The localization of gangliosides in neurons of the central nervous system: the use of anti-ganglioside antibodies. Biochim. Biophys. Acta 1268:247–267. http://dx.doi.org/10.1016/S1388-1981(96)00111-1.

21. Fukuta S, Magnani JL, Twiddy EM, Holmes RK, Ginsburg V. 1988. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins Lth-I, Lltaa, and LT-IBb. Infect Immun 56:1748–1753.

22. Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O. 2005. Plague bacteria target immune cells during infection. Science 309:1741–1744. http://dx.doi.org/10.1126/science.1114580.

23. Zlokarnik G, Negueasca PA, Knapp TE, Mere L, Burres N, Feng L, Whitney M, Roemer K, Tsien RY. 1998. Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Science 279:84–88. http://dx.doi.org/10.1126/science.279.5347.84.

24. Blum FG, Przedpelski A, Tepp WH, Johnson EA, Barbiere JT. 2014. Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells. Infect Immun 82:873–881. http://dx.doi.org/10.1128/IAI.01539-13.

25. Dosta PT, Beristain S, Tomicic TK. 1993. Inhibition of heat-labile cholera toxin and Escherichia coli enterotoxins by brefeldin A. Infect Immun 61:3282–3286.

26. Tremblay JM, Kuo CL, Abejon C, Sepulveda J, Oyler G, Hu X, Jin MM, Shoemaker CB. 2010. Camelid single domain antibodies (VHHS) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon 56:990–998. http://dx.doi.org/10.1016/j.toxicon.2010.07.003.

27. Liang S, Hosur KB, Lu S, Nawar HF, Weber BR, Tapping RI, Connell TD, Hajishengallis G. 2009. Mapping of a microbial protein domain involved in binding and activation of the TLR2/TLR1 heterodimer. Immunol Immunopathol 182:2978–2985. http://dx.doi.org/10.4099/immunopath.8003737.

28. Yuan de Akker F, Safsaf S, Twiddy EM, Connell TD, Holmes RK, Hol WG. 1996. Crystal structure of a new heat-labile enterotoxin, LT-IBb. Structure 4:665–678. http://dx.doi.org/10.1016/S1092-8674(96)00073-1.

29. Whitemarsh RC, Tepp WH, Johnson EA, Pellett S. 2014. Persistence of botulinum neurotoxin A subtypes 1–5 in primary rat spinal cord cells. PLoS One 9:e90252. http://dx.doi.org/10.1371/journal.pone.0090252.

30. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, Tzipori S, Shoemaker CB. 2012. A novel strategy for development of recombinant antibiotic-toxin conjugates tested in a mouse botulism model. PLoS One 7:e29941. http://dx.doi.org/10.1371/journal.pone.0029941.

31. Dong J, Thompson AA, Fan Y, Lou J, Conrado F, Ho M, Pires-Alves M, Wilson BA, Stevens RC, Marks JD. 2010. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol 397:1106–1118. http://dx.doi.org/10.1016/j.jmb.2010.01.070.
33. Zhang P, Ray R, Singh BR, Ray P. 2013. Mastoparan-7 rescues botulinum toxin-A poisoned neurons in a mouse spinal cord cell culture model. Toxicon 76:37–43. http://dx.doi.org/10.1016/j.toxicon.2013.09.002.
34. Zhang P, Ray R, Singh BR, Li D, Adler M, Ray P. 2009. An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol 9:12. http://dx.doi.org/10.1186/1471-2210-9-12.
35. Edupuganti OP, Ovsepian SV, Wang J, Zurawski TH, Schmidt JJ, Smith L, Lawrence GW, Dolly JO. 2012. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J 279:2555–2567. http://dx.doi.org/10.1111/j.1742-4658.2012.08638.x.
36. Jin R, Rummel A, Binz T, Brunger AT. 2006. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444:1092–1095. http://dx.doi.org/10.1038/nature05387.
37. Chai Q, Arndt JW, Dong M, Tepp WH, Johnson EA, Chapman ER, Stevens RC. 2006. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444:1096–1100. http://dx.doi.org/10.1038/nature05411.
38. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592–596. http://dx.doi.org/10.1126/science.1123654.
39. Kuo CL, Oyler GA, Shoemaker CB. 2011. Accelerated neuronal cell recovery from botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One 6:e20352. http://dx.doi.org/10.1371/journal.pone.0020352.
40. Mukherjee J, Dmitriev I, Debatis M, Tremblay JM, Beamer G, Khashentseva EA, Curiel DT, Shoemaker CB. 2014. Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VH H-based antitoxin protein. PLoS One 9:e106422. http://dx.doi.org/10.1371/journal.pone.0106422.
41. Lansbury PT, Lashuel HA. 2006. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443:774–779. http://dx.doi.org/10.1038/nature05290.
42. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. 2008. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neur Clin 26:675–697. http://dx.doi.org/10.1016/j.ncl.2008.03.011.
43. Blum FC, Chen C, Kroken AR, Barbieri JT. 2012. Tetanus toxin and botulinum toxin a utilize unique mechanisms to enter neurons of the central nervous system. Infect Immun 80:1662–1669. http://dx.doi.org/10.1128/IAI.00057-12.
44. Prabakaran S, Tepp W, DasGupta BR. 2001. Botulinum neurotoxin types B and E: purification, limited proteolysis by endoproteinase Glu-C and pepsin, and comparison of their identified cleaved sites relative to the three-dimensional structure of type A neurotoxin. Toxicon 39:1515–1531. http://dx.doi.org/10.1016/S0041-0101(01)00124-6.
45. Malizio CJ, Goodnough MC, Johnson EA. 2000. Purification of Clostridium botulinum type A neurotoxin. Methods Mol Biol 145:27–39. http://dx.doi.org/10.1385/1-59259-052-7:27.